Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Posts Mild Q2 Revenue Growth, Significant Cut in Net Loss

NEW YORK, Aug. 14 (GenomeWeb News) - Genaissance Pharmaceuticals posted a modest increase in second-quarter revenue amid decreased R&D spending and substantially narrowed net losses.


Total revenue for the period ended June 30 inched up to $3.1 million from $1.9 million one year ago.


R&D spending, meantime, dipped to $5 million from $6.6 million. As a result, net loss in the second quarter receded to $3.8 million, or $.17 per share, from $13.5 million, or $.59 per share, in the second quarter last year.


Genaissance said it had around $23.3 million in cash, cash equivalents, and marketable securities as of June 30.


Click here for more information.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.